RT Journal Article
SR Electronic
T1 Synthesis and Biologic Evaluation of <sup>64</sup>Cu-Labeled Rhenium-Cyclized α-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 64
OP 72
VO 48
IS 1
A1 Wei, Lihui
A1 Butcher, Clayton
A1 Miao, Yubin
A1 Gallazzi, Fabio
A1 Quinn, Thomas P.
A1 Welch, Michael J.
A1 Lewis, Jason S.
YR 2007
UL http://jnm.snmjournals.org/content/48/1/64.abstract
AB Early detection of cutaneous melanoma is essential, as prognosis with metastatic melanoma is poor. Previous studies showed that 64Cu-DOTA-ReCCMSH(Arg11) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid), a cyclic analog of α-melanocyte-stimulating hormone (α-MSH), has the potential for the detection of malignant melanoma using PET. However, 64Cu-DOTA-ReCCMSH(Arg11) demonstrated high background in nontarget tissues due to the in vivo instability of the Cu-DOTA moiety. CBTE2A (CBTE2A is 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane) has been shown to be a more stable copper chelate with improved in vivo stability, resulting in an improvement in clearance from nontarget tissues. The goal of this study was to conjugate CBTE2A to the α-MSH targeting ReCCMSH(Arg11) peptide for labeling to 64Cu and to investigate whether the increased metal-chelate stability with CBTE2A would improve imaging quality. Methods: The recyclized peptide CBTE2A-ReCCMSH(Arg11) was synthesized using a solid-phase peptide synthesizer followed by rhenium cyclization. In vivo characteristics of 64Cu-CBTE2A-ReCCMSH(Arg11) were examined with small-animal PET and acute biodistribution studies in B16/F1 tumor-bearing mice. Results: Biodistribution studies showed high and rapid receptor-mediated tumor uptake with values similar to those reported for 64Cu- and 86Y-labeled DOTA-ReCCMSH(Arg11). Nontarget organ concentration for 64Cu-CBTE2A-ReCCMSH(Arg11) was considerably lower than that of the 64Cu-DOTA analog, resulting in significantly higher tumor-to-nontarget tissue ratios. Compared with 86Y-DOTA-ReCCMSH(Arg11), 64Cu-CBTE2A-ReCCMSH(Arg11) demonstrated increased tumor retention and kidney clearance. Small-animal PET images showed that the tumor could be clearly visualized at all time points (0.5–24 h). Conclusion: Our data suggest the superior stability of the 64Cu-CBTE2A moiety compared with 64Cu-DOTA, making 64Cu-CBTE2A-ReCCMSH(Arg11) an ideal candidate for the PET of malignant melanoma.